Passive Biotech

Invesco Biotechnology & Genome ETF

The Invesco Biotechnology & Genome ETF (the “Fund”) seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome Intellidex® Index (the “Underlying Index”).

$64.08

+1.5% last 12 months

Compare similar ETFs

Fund Size
Dividend
Fees
Current
Biotechnology & Genome ETF PBE
Fund Size
$311 Million
Dividend
0.1%
Fees
-
Total Stock Market Index Fund VTI
Fund Size
$1.6 Trillion
Dividend
1.3%
Fees
0.03%
500 Index Fund VOO
Fund Size
$1.11 Trillion
Dividend
1.3%
Fees
0.03%
Core S&P 500 ETF IVV
Fund Size
$456 Billion
Dividend
1.3%
Fees
0.03%
Total International Stock Index Fund VXUS
Fund Size
$404 Billion
Dividend
3.2%
Fees
0.07%
View 1295 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $29.1 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.36 %
Beta Indicates the relationship between the price performance of a share and the market. 0.7541
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 117.49
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -20.86
Profitable Companies 64
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 131.91
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 6.95
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 6.15
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT 23.86
Enterprise Value to Revenue Enterprise value divided by revenue 5.71
Total Debt to Enterprise Value Total debt divided by enterprise value 0.1
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 1.0075
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -16.56%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. 22.81%
Return on Assets Indicates a company's profitability in relation to its total assets. -4.99%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 2.01%

Industries

Healthcare 87.9%
N/A 12.1%

Market cap

Micro Cap 2%
Small Cap 28%
Mid Cap 21%
Large Cap 48%
Mega Cap 0%

33 Investments

P/E-Ratio
Total Investment
Weight
Invesco Private Prime Fund logo

Invesco Private Prime Fund

P/E-Ratio
n/a
Total Investment
$39.4 Million
Weight
15.4%
Illumina, Inc. logo

ILMN - Manufacturing

Illumina, Inc.

P/E-Ratio
-13.5
Total Investment
$16.5 Million
Weight
6.4%
Invesco Private Government Fund logo

Invesco Private Government Fund

P/E-Ratio
n/a
Total Investment
$15.1 Million
Weight
5.9%
Neurocrine Biosciences, Inc. logo

NBIX - Manufacturing

Neurocrine Biosciences, Inc.

P/E-Ratio
37.1
Total Investment
$14.4 Million
Weight
5.6%
Vertex Pharmaceuticals Inc. logo

VRTX - Manufacturing

Vertex Pharmaceuticals Inc.

P/E-Ratio
30.8
Total Investment
$13.6 Million
Weight
5.3%
Amgen Inc. logo

AMGN - Manufacturing

Amgen Inc.

P/E-Ratio
42.6
Total Investment
$13.3 Million
Weight
5.2%
Regeneron Pharmaceuticals, Inc. logo

REGN - Manufacturing

Regeneron Pharmaceuticals, Inc.

P/E-Ratio
28.7
Total Investment
$13.2 Million
Weight
5.2%
Biogen Inc. logo

BIIB - Manufacturing

Biogen Inc.

P/E-Ratio
29.2
Total Investment
$12 Million
Weight
4.7%
ImmunoGen, Inc. logo

IMGN - Manufacturing

ImmunoGen, Inc.

P/E-Ratio
0.0
Total Investment
$12 Million
Weight
4.7%
BioMarin Pharmaceutical Inc. logo

BMRN - Manufacturing

BioMarin Pharmaceutical Inc.

P/E-Ratio
77.9
Total Investment
$11.3 Million
Weight
4.4%
United Therapeutics Corp. logo

UTHR - Manufacturing

United Therapeutics Corp.

P/E-Ratio
12.1
Total Investment
$10.5 Million
Weight
4.1%
Celldex Therapeutics, Inc. logo

CLDX - Manufacturing

Celldex Therapeutics, Inc.

P/E-Ratio
-16.6
Total Investment
$7.93 Million
Weight
3.1%
Collegium Pharmaceutical, Inc. logo

COLL - Manufacturing

Collegium Pharmaceutical, Inc.

P/E-Ratio
11.2
Total Investment
$7.89 Million
Weight
3.1%
TG Therapeutics, Inc. logo

TGTX - Manufacturing

TG Therapeutics, Inc.

P/E-Ratio
62.3
Total Investment
$7.76 Million
Weight
3.0%
Repligen Corp. logo

RGEN - Manufacturing

Repligen Corp.

P/E-Ratio
474.1
Total Investment
$7.46 Million
Weight
2.9%
Blueprint Medicines Corp. logo

BPMC - Manufacturing

Blueprint Medicines Corp.

P/E-Ratio
-23.1
Total Investment
$7.4 Million
Weight
2.9%
Myriad Genetics, Inc. logo

MYGN - Manufacturing

Myriad Genetics, Inc.

P/E-Ratio
-9.0
Total Investment
$7.26 Million
Weight
2.8%
PTC Therapeutics, Inc. logo

PTCT - Manufacturing

PTC Therapeutics, Inc.

P/E-Ratio
-4.9
Total Investment
$7.21 Million
Weight
2.8%
Vericel Corp. logo

VCEL - Manufacturing

Vericel Corp.

P/E-Ratio
4671.6
Total Investment
$7.18 Million
Weight
2.8%
Intra-Cellular Therapies, Inc. logo

ITCI - Manufacturing

Intra-Cellular Therapies, Inc.

P/E-Ratio
0.0
Total Investment
$7.05 Million
Weight
2.8%
Acadia Pharmaceuticals Inc. logo

ACAD - Manufacturing

Acadia Pharmaceuticals Inc.

P/E-Ratio
-1458.0
Total Investment
$6.93 Million
Weight
2.7%
Alkermes PLC logo

Alkermes PLC

P/E-Ratio
n/a
Total Investment
$6.86 Million
Weight
2.7%
Arrowhead Pharmaceuticals, Inc. logo

ARWR - Manufacturing

Arrowhead Pharmaceuticals, Inc.

P/E-Ratio
-7.0
Total Investment
$6.81 Million
Weight
2.7%
Qiagen N.V. logo

QGEN - Manufacturing

Qiagen N.V.

P/E-Ratio
29.4
Total Investment
$6.7 Million
Weight
2.6%
Catalyst Pharmaceuticals, Inc. logo

CPRX - Manufacturing

Catalyst Pharmaceuticals, Inc.

P/E-Ratio
27.8
Total Investment
$6.44 Million
Weight
2.5%